Hutch News

Hutch News

Stories tagged 'clinical trials'

For cancer patients with HIV, immunotherapy appears safe

Checkpoint inhibitor study suggests new treatment options for patients long excluded from cancer immunotherapy clinical trials

Nov. 7, 2017 | By Mary Engel / Fred Hutch News Service

Checkpoint inhibitor study suggests new treatment options for patients long excluded from cancer immunotherapy clinical trials.

View story >


New insights into CAR T-cell therapy's potential side effects

Detailed study of cytokine release syndrome and neurologic toxicities could help make emerging cancer immunotherapies safer

Oct. 11, 2017 | By Fred Hutch staff

Detailed studies of two potential side effects of an emerging cancer immunotherapy could eventually help make this strategy, CAR T-cell therapy, safer for patients. The studies examined cytokine release syndrome and neurologic toxicities.

View story >


One family, two sides of cancer

Basic scientist Dr. Wenying Shou’s parents were both treated for — and cured of — their cancers. The similarities end there.

Oct. 6, 2017 | By Rachel Tompa / Fred Hutch News Service

Both of Dr. Wenying Shou's parents were diagnosed with - and cured of - cancer. The similarities end there.

View story >


Teacher, mom — and living proof of principle

Three years ago she was out of options to treat her advanced cancer. Then, she enrolled in an immunotherapy clinical trial.

Sept. 8, 2017 | By Susan Keown / Fred Hutch News Service

When Tiffany's advanced cancer kept coming back, she decided to become the first person in the world to receive a still-experimental new immunotherapy.

View story >


Scared — and brave

Why volunteer for an HIV cure study? A community group undertakes its own research to find out

June 14, 2017 | By Mary Engel / Fred Hutch News Service

People who volunteer for HIV cure studies “want to feel like they’re contributing to the greater body of knowledge,” according to a community-led study. “But they want to feel like they can trust [the researchers], like they’re being treated with respect.”

View story >


Experimental herpes drug more effective than standard treatment

Pritelivir reduces viral shedding and lesions better than valacyclovir, study shows

Dec. 20, 2016 | By Mary Engel / Fred Hutch News Service

The results of the phase 2, randomized, double-blind trial published today in JAMA showed that when people with genital herpes took a daily oral dose of pritelivir, they reduced their rate of viral shedding by half compared to when they took valacyclovir. They also had fewer genital sores and less pain.

View story >



GIVE NOW &
SAVE LIVES

Support our quest for cures

Story Archive


Publications

Hutch Magazine
Our quarterly magazine

Annual Report
Fiscal year highlights

Science Spotlight
Monthly review of Center-authored papers



Fred Hutch News

        Get updates via email.